|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EXOSC6 |
Gene summary for EXOSC6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EXOSC6 | Gene ID | 118460 |
| Gene name | exosome component 6 | |
| Gene Alias | EAP4 | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | Q5RKV6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 118460 | EXOSC6 | C04 | Human | Oral cavity | OSCC | 1.85e-06 | 5.88e-01 | 0.2633 |
| 118460 | EXOSC6 | C21 | Human | Oral cavity | OSCC | 8.46e-40 | 1.28e+00 | 0.2678 |
| 118460 | EXOSC6 | C30 | Human | Oral cavity | OSCC | 1.37e-30 | 1.47e+00 | 0.3055 |
| 118460 | EXOSC6 | C43 | Human | Oral cavity | OSCC | 6.94e-10 | 3.35e-01 | 0.1704 |
| 118460 | EXOSC6 | C46 | Human | Oral cavity | OSCC | 7.00e-03 | 7.43e-02 | 0.1673 |
| 118460 | EXOSC6 | C06 | Human | Oral cavity | OSCC | 1.80e-04 | 9.01e-01 | 0.2699 |
| 118460 | EXOSC6 | C08 | Human | Oral cavity | OSCC | 9.87e-24 | 5.28e-01 | 0.1919 |
| 118460 | EXOSC6 | SYSMH1 | Human | Oral cavity | OSCC | 1.61e-16 | 4.27e-01 | 0.1127 |
| 118460 | EXOSC6 | SYSMH2 | Human | Oral cavity | OSCC | 5.81e-22 | 7.93e-01 | 0.2326 |
| 118460 | EXOSC6 | SYSMH3 | Human | Oral cavity | OSCC | 1.69e-31 | 8.60e-01 | 0.2442 |
| 118460 | EXOSC6 | SYSMH4 | Human | Oral cavity | OSCC | 8.70e-06 | 1.00e-01 | 0.1226 |
| 118460 | EXOSC6 | SYSMH5 | Human | Oral cavity | OSCC | 4.83e-11 | 4.48e-01 | 0.0647 |
| 118460 | EXOSC6 | male-WTA | Human | Thyroid | PTC | 1.76e-23 | 2.60e-01 | 0.1037 |
| 118460 | EXOSC6 | PTC01 | Human | Thyroid | PTC | 3.51e-17 | 2.41e-01 | 0.1899 |
| 118460 | EXOSC6 | PTC03 | Human | Thyroid | PTC | 7.49e-04 | 1.37e-01 | 0.1784 |
| 118460 | EXOSC6 | PTC04 | Human | Thyroid | PTC | 2.66e-12 | 2.27e-01 | 0.1927 |
| 118460 | EXOSC6 | PTC05 | Human | Thyroid | PTC | 7.19e-15 | 5.84e-01 | 0.2065 |
| 118460 | EXOSC6 | PTC06 | Human | Thyroid | PTC | 6.01e-30 | 5.66e-01 | 0.2057 |
| 118460 | EXOSC6 | PTC07 | Human | Thyroid | PTC | 2.03e-37 | 5.44e-01 | 0.2044 |
| 118460 | EXOSC6 | ATC09 | Human | Thyroid | ATC | 3.06e-04 | 2.55e-01 | 0.2871 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:001607210 | Oral cavity | OSCC | rRNA metabolic process | 176/7305 | 236/18723 | 6.51e-29 | 3.24e-26 | 176 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:000640118 | Oral cavity | OSCC | RNA catabolic process | 184/7305 | 278/18723 | 2.71e-20 | 4.19e-18 | 184 |
| GO:000640218 | Oral cavity | OSCC | mRNA catabolic process | 156/7305 | 232/18723 | 2.13e-18 | 2.37e-16 | 156 |
| GO:003465517 | Oral cavity | OSCC | nucleobase-containing compound catabolic process | 244/7305 | 407/18723 | 5.38e-18 | 5.49e-16 | 244 |
| GO:004670015 | Oral cavity | OSCC | heterocycle catabolic process | 254/7305 | 445/18723 | 5.07e-15 | 3.31e-13 | 254 |
| GO:004427016 | Oral cavity | OSCC | cellular nitrogen compound catabolic process | 256/7305 | 451/18723 | 9.67e-15 | 5.88e-13 | 256 |
| GO:001943915 | Oral cavity | OSCC | aromatic compound catabolic process | 263/7305 | 467/18723 | 1.49e-14 | 8.84e-13 | 263 |
| GO:190136115 | Oral cavity | OSCC | organic cyclic compound catabolic process | 272/7305 | 495/18723 | 2.73e-13 | 1.36e-11 | 272 |
| GO:005105210 | Oral cavity | OSCC | regulation of DNA metabolic process | 207/7305 | 359/18723 | 4.45e-13 | 2.17e-11 | 207 |
| GO:000095610 | Oral cavity | OSCC | nuclear-transcribed mRNA catabolic process | 81/7305 | 112/18723 | 7.95e-13 | 3.70e-11 | 81 |
| GO:005105414 | Oral cavity | OSCC | positive regulation of DNA metabolic process | 126/7305 | 201/18723 | 8.12e-12 | 3.01e-10 | 126 |
| GO:00002912 | Oral cavity | OSCC | nuclear-transcribed mRNA catabolic process, exonucleolytic | 19/7305 | 19/18723 | 1.69e-08 | 3.36e-07 | 19 |
| GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
| GO:00710251 | Oral cavity | OSCC | RNA surveillance | 15/7305 | 15/18723 | 7.33e-07 | 1.03e-05 | 15 |
| GO:00710272 | Oral cavity | OSCC | nuclear RNA surveillance | 13/7305 | 13/18723 | 4.82e-06 | 5.48e-05 | 13 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EXOSC6 | SNV | Missense_Mutation | novel | c.761N>A | p.Val254Glu | p.V254E | Q5RKV6 | protein_coding | deleterious(0) | benign(0.106) | TCGA-2A-A8W3-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |